Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2017

Summary

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance. 

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Ophthalmology, Cardiovascular, Dermatology and Immunology which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Glaucoma, Cardiomyopathy, Cushing's Syndrome, Dementia Associated With Alzheimer's Disease, Inflammation, Intracranial Hypertension, Metabolic Syndrome, Ocular Hypertension, Open-Angle Glaucoma, Osteopenia, Psychiatric Disorders and Wounds. 

The latest report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Overview 7
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development 19
Actinogen Medical Ltd 19
Astellas Pharma Inc 19
AstraZeneca Plc 20
Boehringer Ingelheim GmbH 20
Connexios Life Sciences Pvt Ltd 20
F. Hoffmann-La Roche Ltd 21
Hyundai Pharmaceutical Co Ltd 21
Laboratorios SALVAT SA 22
Poxel SA 22
SK Chemicals Co Ltd 23
Toray Industries Inc 23
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles 24
ASP-3662 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
AZD-4017 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
BI-135558 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CNX-1049 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
HIS-388 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HOB-046 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
KR-66344 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
NCE-402 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
RO-5093151 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
SVT-63 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
SVT-88 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
TR-013A - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
UE-2343 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Products 44
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products 46
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Product Development Milestones 47
Featured News & Press Releases 47
Sep 07, 2017: Actinogen Medical: First patient completes landmark Alzheimer's disease trial 47
Aug 16, 2017: First UK patient treated in ground-breaking Alzheimer's clinical trial 47
Jul 26, 2017: Actinogen Medical Provides Update on Xanamem 48
Jun 22, 2017: First US patients treated in landmark Alzheimers disease trial 50
Jun 01, 2017: First UK site goes live in global Alzheimer's disease clinical trial 51
May 16, 2017: First patient treated in landmark Alzheimer's disease clinical trial 51
Apr 26, 2017: Actinogen provides March quarterly update 52
Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer's Phase II Trial 54
Feb 27, 2017: Actinogen announce Medical Half-Year Results 55
Feb 09, 2017: Xanamem research published in prestigious medical journal 56
Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial - XanADu 57
Jan 03, 2017: FDA Approval to Commence Alzheimer's Disease Clinical Trial 58
Dec 19, 2016: Significant Advance In Development Of Actinogen Medical Alzheimer's Drug Xanamem 58
Dec 06, 2016: Actinogen Medical: Xanamem Research Presented At CTAD 59
Sep 29, 2016: FDA Feedback On Xanamem Alzheimers Trial 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Actinogen Medical Ltd, H2 2017 19
Pipeline by Astellas Pharma Inc, H2 2017 19
Pipeline by AstraZeneca Plc, H2 2017 20
Pipeline by Boehringer Ingelheim GmbH, H2 2017 20
Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017 21
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 21
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017 22
Pipeline by Laboratorios SALVAT SA, H2 2017 22
Pipeline by Poxel SA, H2 2017 23
Pipeline by SK Chemicals Co Ltd, H2 2017 23
Pipeline by Toray Industries Inc, H2 2017 23
Dormant Products, H2 2017 44
Dormant Products, H2 2017 (Contd..1), H2 2017 45
Discontinued Products, H2 2017 46